Fabrice Barlési

Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

H. Borghaei, L. Paz-Ares, Leora Horn et al. · New England Journal of Medicine · 2015 · 9.3K citations · Full text

Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial

Achim Rittmeyer, Fabrice Barlési, Daniel Waterkamp et al. · The Lancet · 2016 · 4.7K citations · Full text

Non-small-cell Lung Cancer, Medicine, Metronomic Therapy +12

Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC

Mark A. Socinski, Robert M. Jotte, Federico Cappuzzo et al. · New England Journal of Medicine · 2018 · 3.7K citations · Full text

Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer

Matthew D. Hellmann, Luis Paz‐Ares, Reyes Bernabé et al. · New England Journal of Medicine · 2019 · 2.8K citations · Full text

Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Silvia Novello, Fabrice Barlési, Raffaele Califano et al. · Annals of Oncology · 2016 · 2.6K citations

Medicine, Cancer Management, Pulmonary Blastoma +5